Voglibose , 98% , 83480-29-9

Synonym(s):
3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol;N-(1,3-Dihydroxyprop-2-yl)valiolamine

CAS NO.：83480-29-9

Empirical Formula: C10H21NO7

Molecular Weight: 267.28

MDL number: MFCD00865496

EINECS: 1312995-182-4

PRODUCT Properties

• Melting point: 162-163°C
• alpha: D25 +26.2° (c = 1 in water)
• Boiling point: 601.9±55.0 °C(Predicted)
• Density: 1.58±0.1 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: DMSO (Slightly), Methanol (Very Slightly, Heated), Water (Sparingly, Sonicated)
• form: Solid
• pka: 13.26±0.70(Predicted)
• color: White to Off-White
• Merck: 14,10029
• InChIKey: FZNCGRZWXLXZSZ-CIQUZCHMSA-N

Description and Uses

Voglibose was introduced in Japan for the treatment of postprandial hyperglycemia in diabetic patients. As an orally active α-D-glucosidase inhibitor, it is effective in decreasing the release of glucose from carbohydrate ingestion and slowing the increase of postprandial blood glucose levels, as demonstrated in animals and humans following sucrose and starch loading. In addlion, voglibose was reported to have prophylactic effect in genetically obese Wistar rats, maintaining low plasma levels of glucose, triglyceride and insulin, indicating a potential usefulness for the management of other carbohydrate-dependent metabolic disorders such as obesity. Voglibose is much more potent and has fewer side effects than acarbose, another agent in its class.

For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• Hazard Codes: Xi
• Risk Statements: 20/21/22-36/37/38
• Safety Statements: 36/37-37/39-26
• WGK Germany: 3
• RTECS: NM7524600
• HS Code: 2940.00.6000